PAI-1

Mouse recombinant PAI-1 (0.01-1 μg/mL; 90 min) dose-dependently inhibits phagocytosis of viable PAI-1^-/- mouse bone marrow neutrophils by mouse peritoneal macrophages, with 1 μg/mL PAI-1 reducing phagocytic index to wild-type levels^[1].
Rabbit anti-PAI-1 antibodies (1 μg/mL; 90 min) significantly enhance phagocytosis of viable wild-type mouse bone marrow neutrophils by mouse peritoneal macrophages, a PAI-1-dependent effect^[1].
Mouse recombinant PAI-1 (1 μg/mL; 90 min) inhibits the enhanced phagocytosis of viable wild-type mouse bone marrow neutrophils by mouse peritoneal macrophages induced by CD47 blockade^[1].
Mouse recombinant PAI-1 (1 μg/mL) reduces elevated surface calreticulin levels on viable PAI-1^-/- mouse bone marrow neutrophils to wild-type levels^[1].
Mouse recombinant PAI-1 (1 μg/mL; 90 min) significantly inhibits phagocytosis of apoptotic wild-type mouse bone marrow neutrophils by mouse peritoneal macrophages^[1].
Active human PAI-1 potently inhibits human tPA and uPA with second-order rate constants between 10⁶ and 10⁷ M^-1 s^-1 via a canonical serpin-mediated inhibitory mechanism^[2].
PAI-1 controls collagen levels, a key profibrotic marker, in human keloid-derived skin fibroblasts, with overexpression increasing collagen accumulation and depletion reducing it^[3].
PAI-1 (5 μg; 2 h at 4°C) and Guanidine hydrochloride (HY-B0178A)-activated PAI-1 (4 M; 2 h at 20°C pre-treatment) bind to Heparin (HY-17567)-Sepharose at pH 7.4, with non-activated PAI-1 exhibiting a sharper elution profile at higher Na⁺Cl⁻ concentrations than activated PAI-1^[5].
PAI-1 has binding to heparin-Sepharose competed by soluble heparin and low molecular weight heparin, with soluble heparin exhibiting ~10-fold higher affinity for PAI-1 than low molecular weight heparin, as indicated by IC₅₀ values of 7.0 μM and 73 μM, respectively^[5].
PAI-1 (5 nM; 1 h at 37°C) has heparin dose-dependently mediate inhibition of α-thrombin, with maximal inhibition at 1 unit/mL heparin and a corresponding second-order association rate constant of 1.0 × 10⁵ M^-1s^-1[5].
PAI-1 (7 nM; 1 h at 37°C) has heparin dose-dependently promote the formation of SDS-stable complexes with human α-thrombin, with maximal complex formation occurring at 1 unit/mL heparin^[5].
PAI-1 potently inhibits the enzymatic activity of free tPA, reducing its activity by 82% when used at equivalent molar amounts^[9].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.